G protein-coupled receptors as targets for anti-diabetic therapeutics

Nature Reviews Drug Discovery

Volumn 15, Issue 3, 2016, Pages 161-172

  Oh, Da Young ^a   Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIDIABETIC AGENT; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE RECEPTOR 1 LIGAND 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOCOSAHEXAENOIC ACID; FASIGLIFAM; FREE FATTY ACID RECEPTOR 4; FREE FATTY ACID RECEPTOR 4 AGONIST; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 40; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE-DEPENDENT INSULINOTROPIC RECEPTOR; ICOSAPENTAENOIC ACID; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE B4 RECEPTOR 1; LEUKOTRIENE B4 RECEPTOR 2; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LIGAND; PHOSPHOLIPASE C; RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; METABOLISM; OBESITY; PHYSIOLOGY; PROCEDURES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84959340392     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.4     Document Type: Review

References (206)

1. Kahn, S. E., Hull, R. L., & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840-846 (2006
2. Olefsky, J. M., & Courtney, C. H. in Textook of Endocrinology 5th edn (eds DeGroot, J., & Jameson, J. L.) 1093-1117 (W. B. Saunders and Company, 2005
3. Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333-1346 (2005
4. Barnes, A. S. The epidemic of obesity and diabetes: trends and treatments. Tex. Heart Inst. J. 38, 142-144 (2011
5. Cerf, M. E. Beta cell dysfunction and insulin resistance. Front. Endocrinol. (Lausanne) 4, 37 (2013
6. Nolan, C. J., & Prentki, M. The islet β-cell: fuel responsive and vulnerable. Trends Endocrinol. Metab. 19, 285-291 (2008
7. Prentki, M., & Nolan, C. J. Islet β cell failure in type 2 diabetes. J. Clin. Invest. 116, 1802-1812 (2006
8. Bornfeldt, K. E., & Tabas, I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 14, 575-585 (2011
9. Imai, Y., Dobrian, A. D., Morris, M. A., & Nadler, J. L. Islet inflammation: a unifying target for diabetes treatment?. Trends Endocrinol. Metab. 24, 351-360 (2013
10. Johnson, A. M., & Olefsky, J. M. The origins and drivers of insulin resistance. Cell 152, 673-684 (2013
11. Robertson, R. P. â-cell deterioration during diabetes: what's in the gun?. Trends Endocrinol. Metab. 20, 388-393 (2009
12. Saltiel, A. R. Insulin resistance in the defense against obesity. Cell Metab. 15, 798-804 (2012
13. Samuel, V. T., & Shulman, G. I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871 (2012
14. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90-113 (2000
15. Katritch, V., Cherezov, V., & Stevens, R. C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53, 531-556 (2013
16. Kobilka, B. K. G protein coupled receptor structure and activation. Biochim. Biophys. Acta 1768, 794-807 (2007
17. Claing, A., Laporte, S. A., Caron, M. G., & Lefkowitz, R. J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-Arrestin proteins. Prog. Neurobiol. 66, 61-79 (2002
18. Hall, R. A., & Lefkowitz, R. J. Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ. Res. 91, 672-680 (2002
19. Pierce, K. L., et al. Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co culture system for identifying intermediates upstream and downstream of heparin binding EGF shedding. J. Biol. Chem. 276, 23155-23160 (2001
20. Zhang, J., et al. Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Recept. Channels 5, 193-199 (1997
21. Ahren, B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat. Rev. Drug Discov. 8, 369-385 (2009
22. Berger, M., et al. Gαi/o coupled receptor signaling restricts pancreatic β-cell expansion. Proc. Natl Acad. Sci. USA 112, 2888-2893 (2015
23. Kim, H., et al. Serotonin regulates pancreatic β-cell mass during pregnancy. Nat. Med. 16, 804-808 (2010
24. McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., & Roche, H. M. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front. Endocrinol. (Lausanne) 4, 52 (2013
25. Shoelson, S. E., Lee, J., & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006
26. Weisberg, S. P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003
27. Xu, H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821-1830 (2003
28. Chawla, A., Nguyen, K. D., & Goh, Y. P. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11, 738-749 (2011
29. Li, P., et al. Functional heterogeneity of CD11c positive adipose tissue macrophages in diet-induced obese mice. J. Biol. Chem. 285, 15333-15345 (2010
30. Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007
31. Olefsky, J. M., & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010
32. Talukdar, S., et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407-1412 (2012
33. Winer, D. A., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610-617 (2011
34. Gerner, R. R., Wieser, V., Moschen, A. R., & Tilg, H. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can. J. Physiol. Pharmacol. 91, 867-872 (2013
35. Wieser, V., Moschen, A. R., & Tilg, H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch. Immunol. Ther. Exp. (Warsz) 61, 119-125 (2013
36. Folco, G., & Murphy, R. C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58, 375-388 (2006
37. Samuelsson, B., & Funk, C. D. Enzymes involved in the biosynthesis of leukotriene B4. J. Biol. Chem. 264, 19469-19472 (1989
38. Dixon, R. A., et al. Requirement of a 5 lipoxygenase-Activating protein for leukotriene synthesis. Nature 343, 282-284 (1990
39. Peters-Golden, M., & Henderson, W. R. Jr. Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007
40. Radmark, O., & Samuelsson, B. 5 lipoxygenase: mechanisms of regulation. J. Lipid Res. 50, S40-S45 (2009
41. Afonso, P. V., et al. LTB4 is a signal-relay molecule during neutrophil chemotaxis. Dev. Cell 22, 1079-1091 (2012
42. Kavelaars, A., et al. Increased acute inflammation, leukotriene B4 induced chemotaxis, and signaling in mice deficient for G protein-coupled receptor kinase 6. J. Immunol. 171, 6128-6134 (2003
43. Rankin, J. A., Sylvester, I., Smith, S., Yoshimura, T., & Leonard, E. J. Macrophages cultured in vitro release leukotriene B4 and neutrophil attractant/activation protein (interleukin 8) sequentially in response to stimulation with lipopolysaccharide and zymosan. J. Clin. Invest. 86, 1556-1564 (1990
44. Tian, W., et al. Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension. Sci. Transl. Med. 5, 200ra117 (2013
45. Tong, W. G., et al. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 8, 3232-3242 (2002
46. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., & Shimizu, T. A. G protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387, 620-624 (1997
47. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., & Shimizu, T. A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192, 421-432 (2000
48. Hill, A. T., Bayley, D., & Stockley, R. A. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 160, 893-898 (1999
49. Montuschi, P., Kharitonov, S. A., Ciabattoni, G., & Barnes, P. J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 58, 585-588 (2003
50. Chen, M., et al. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 203, 837-842 (2006
51. Xu, S., Lu, H., Lin, J., Chen, Z., & Jiang, D. Regulation of TNFα and IL1β in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol. Int. 30, 1183-1189 (2010
52. Beeh, K M., et al. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123, 1240-1247 (2003
53. Crooks, S. W., Bayley, D. L., Hill, S. L., & Stockley, R. A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur. Respir. J. 15, 274-280 (2000
54. Hicks, A., Monkarsh, S. P., Hoffman, A. F., & Goodnow, R. Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin. Investig. Drugs 16, 1909-1920 (2007
55. Nancey, S., et al. Blockade of LTB4/BLT1 pathway improves CD8+ T cell-mediated colitis. Inflamm. Bowel Dis. 17, 279-288 (2011
56. Showell, H. J., Breslow, R., Conklyn, M. J., Hingorani, G. P., & Koch, K. Characterization of the pharmacological profile of the potent LTB4 antagonist CP 105, 696 on murine LTB4 receptors in vitro. Br. J. Pharmacol. 117, 1127-1132 (1996
57. Gronke, L., et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 21, 409-417 (2008
58. Spite, M., et al. Deficiency of the leukotriene B4 receptor, BLT 1, protects against systemic insulin resistance in diet-induced obesity. J. Immunol. 187, 1942-1949 (2011
59. Li, P., et al. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 21, 239-247 (2015
60. González-Périz, A., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ? 3 fatty acids: a role for resolvins and protectins. Faseb J. 23, 1946-1957 (2009
61. Proudman, S. M., Cleland, L. G., & James, M. J. Dietary omega 3 fats for treatment of inflammatory joint disease: efficacy and utility. Rheum. Dis. Clin. North Am. 34, 469-479 (2008
62. Sijben, J. W., & Calder, P. C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 66, 237-259 (2007
63. Calder, P. C. Omega 3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br. J. Clin. Pharmacol. 75, 645-662 (2013
64. Sorensen, L. S., et al. Rapid incorporation of ? 3 fatty acids into colonic tissue after oral supplementation in patients with colorectal cancer: a randomized, placebo-controlled intervention trial. J. Parenter. Enteral Nutr. 38, 617-624 (2013
65. Sorensen, L. S., et al. Randomized clinical trial of perioperative omega 3 fatty acid supplements in elective colorectal cancer surgery. Br. J. Surg. 101, 33-42 (2014
66. Yates, C. M., Calder, P. C., & Ed Rainger, G. Pharmacology and therapeutics of omega 3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol. Ther. 141, 272-282 (2014
67. Yusof, H. M., et al. Limited impact of 2 g/day omega 3 fatty acid ethyl esters (Omacor®) on plasma lipids and inflammatory markers in patients awaiting carotid endarterectomy. Mar. Drugs 11, 3569-3581 (2013
68. Cintra, D. E., et al. Unsaturated fatty acids revert diet induced hypothalamic inflammation in obesity. PLoS ONE 7, e30571 (2012
69. Oh, D. Y., et al. GPR120 is an omega 3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698 (2010
70. Williams-Bey, Y., et al. Omega 3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF ?B activation and enhancing autophagy. PLoS ONE 9, e97957 (2014
71. Yan, Y., et al. Omega 3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38, 1154-1163 (2013
72. Hirasawa, A., et al. Free fatty acids regulate gut incretin glucagon-like peptide 1 secretion through GPR120. Nat. Med. 11, 90-94 (2005
73. Gotoh, C., et al. The regulation of adipogenesis through GPR120. Biochem. Biophys. Res. Commun. 354, 591-597 (2007
74. Christiansen, E., et al. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br. J. Nutr. 113, 1677-1688 (2015
75. Burns, R. N., & Moniri, N. H. Agonism with the omega 3 fatty acids α-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem. Biophys. Res. Commun. 396, 1030-1035 (2010
76. Hudson, B. D., et al. The pharmacology of TUG 891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84, 710-725 (2013
77. Li, X., Yu, Y., & Funk, C. D. Cyclooxygenase 2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J. 27, 4987-4997 (2013
78. Liu, Y., et al. The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce prostaglandin E2 and plays an anti-inflammatory role in macrophages. Immunology 143, 81-95 (2014
79. Liu, Z., et al. Omega 3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells. J. Pharmacol. Exp. Ther. 352, 380-394 (2015
80. Raptis, D. A., et al. GPR120 on Kupffer cells mediates hepatoprotective effects of ?3 fatty acids. J. Hepatol 60, 625-632 (2014
81. Wellhauser, L., & Belsham, D. D. Activation of the omega 3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J. Neuroinflamm. 11, 60 (2014
82. Watson, S. J., Brown, A. J., & Holliday, N. D. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol. Pharmacol. 81, 631-642 (2012
83. Burns, R. N., Singh, M., Senatorov, I. S., & Moniri, N. H. Mechanisms of homologous and heterologous phosphorylation of FFA receptor 4 (GPR120): GRK6 and PKC mediate phosphorylation of Thr347, Ser350, and Ser357 in the C terminal tail. Biochem. Pharmacol. 87, 650-659 (2014
84. Ichimura, A., et al. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483, 350-354 (2012
85. Bonnefond, A., et al. Contribution of the low-frequency, loss of function p.R270H mutation in FFAR4 (GPR120) to increased fasting plasma glucose levels. J. Med. Genet. 52, 595-598 (2015
86. de Git, K. C., & Adan, R. A. Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes. Rev. 16, 207-224 (2015
87. Milanski, M., et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J. Neurosci. 29, 359-370 (2009
88. Suckow, A. T., et al. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J. Biol. Chem. 289, 15751-15763 (2014
89. Yore, M. M., et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159, 318-332 (2014
90. Oh da, Y., et al. A Gpr120 selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20, 942-947 (2014
91. Meier, J. J. GLP 1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728-742 (2012
92. Peters, A. Incretin-based therapies: review of current clinical trial data. Am. J. Med. 123, S28-S37 (2010
93. Tzefos, M., Harris, K., & Brackett, A. Clinical efficacy and safety of once-weekly glucagon-like peptide 1 agonists in development for treatment of type 2 diabetes mellitus in adults. Ann. Pharmacother. 46, 68-78 (2012
94. Fonseca, V. A., et al. Efficacy and safety of the once-daily GLP 1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35, 1225-1231 (2012)
95. Grunberger, G., et al. Monotherapy with the once-weekly GLP 1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet. Med. 29, 1260-1267 (2012
96. Cuthbertson, J., Patterson, S., O'Harte, F. P., & Bell, P. M. Addition of metformin to exogenous glucagon-like peptide 1 results in increased serum glucagon-like peptide 1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 60, 52-56 (2011
97. Migoya, E. M., et al. Dipeptidyl peptidase 4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP 1. Clin. Pharmacol. Ther. 88, 801-808 (2010
98. Zander, M., Taskiran, M., Toft-Nielsen, M. B., Madsbad, S., & Holst, J. J. Additive glucose-lowering effects of glucagon-like peptide 1 and metformin in type 2 diabetes. Diabetes Care 24, 720-725 (2001
99. Vella, A. Common genetic variation influences the heterogeneity of response to oral glucose. Curr. Diab. Rep. 10, 249-251 (2010
100. Drucker, D. J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17, 161-171 (2003
101. Drucker, D. J. The biology of incretin hormones. Cell Metab. 3, 153-165 (2006
102. Drucker, D. J. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117, 24-32 (2007
103. Ahren, B., & Schmitz, O. GLP 1 receptor agonists and DPP 4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 36, 867-876 (2004
104. Brown, D. X., & Evans, M. Choosing between GLP 1 receptor agonists and DPP 4 inhibitors: a pharmacological perspective. J. Nutr. Metab. 2012, 381713 (2012
105. Brunton, S. GLP 1 receptor agonists versus DPP 4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. Int. J. Clin. Pract. 68, 557-567 (2014
106. Unger, J. R., & Parkin, C. G. Glucagon-like peptide 1 (GLP 1) receptor agonists: differentiating the new medications. Diabetes Ther. 2, 29-39 (2011
107. Dicker, D. DPP 4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34, S276-S278 (2011
108. Doyle, M. E., & Egan, J. M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113, 546-593 (2007
109. Sonoda, N., et al. β-Arrestin 1 mediates glucagon-like peptide 1 signaling to insulin secretion in cultured pancreatic β cells. Proc. Natl Acad. Sci. USA 105, 6614-6619 (2008
110. Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271, E458-E464 (1996
111. Hansen, L., Deacon, C. F., Orskov, C., & Holst, J. J. Glucagon-like peptide 1-(7-36)amide is transformed to glucagon-like peptide 1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140, 5356-5363 (1999
112. Vilsboll, T., Agerso, H., Krarup, T., & Holst, J. J. Similar elimination rates of glucagon-like peptide 1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220-224 (2003
113. Farre, R., & Tack, J. Food and symptom generation in functional gastrointestinal disorders: physiological aspects. Am. J. Gastroenterol. 108, 698-706 (2013
114. Richards, P., et al. Identification and characterization of GLP 1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63, 1224-1233 (2014
115. Sisley, S., et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J. Clin. Invest. 124, 2456-2463 (2014
116. Lamont, B. J., et al. Pancreatic GLP 1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122, 388-402 (2012
117. Buteau, J., Foisy, S., Joly, E., & Prentki, M. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52, 124-132 (2003
118. Wang, Q., & Brubaker, P. L. Glucagon-like peptide 1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45, 1263-1273 (2002
119. Fehmann, H. C., Goke, R., & Goke, B. Cell and molecular biology of the incretin hormones glucagon-like peptide I and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16, 390-410 (1995
120. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007
121. Orskov, C., Holst, J. J., & Nielsen, O. V. Effect of truncated glucagon-like peptide 1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123, 2009-2013 (1988
122. Baynes, K. C. The evolving world of GLP 1 agonist therapies for type 2 diabetes. Ther. Adv. Endocrinol. Metab. 1, 61-67 (2010
123. Secher, A., et al. The arcuate nucleus mediates GLP 1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 124, 4473-4488 (2014
124. Buse, J. B., et al. Use of twice-daily exenatide in basal insulin-Treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Intern. Med. 154, 103-112 (2011
125. Madsbad, S. Exenatide and liraglutide: different approaches to develop GLP 1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 23, 463-477 (2009
126. Stonehouse, A., Walsh, B., & Cuddihy, R. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. Diabetes Technol. Ther. 13, 1063-1069 (2011
127. Freyse, E. J., Berg, S., Kohnert, K. D., Heinke, P., & Salzsieder, E. DPP 4 inhibition increases GIP and decreases GLP 1 incretin effects during intravenous glucose tolerance test in Wistar rats. Biol. Chem. 392, 209-215 (2011
128. Kazafeos, K. Incretin effect: GLP 1, GIP, DPP4. Diabetes Res. Clin. Pract. 93, S32-S36 (2011
129. Nikolaidis, L. A., et al. Effects of glucagon-like peptide 1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (2004
130. Read, P. A., et al. A pilot study to assess whether glucagon-like peptide 1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4, 266-272 (2011
131. Sokos, G. G., et al. Effect of glucagon-like peptide 1 (GLP 1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100, 824-829 (2007
132. Stranges, P., & Khanderia, U. Diabetes and cardiovascular disease: focus on glucagon-like peptide 1 based therapies. Ther. Adv. Drug Saf. 3, 185-201 (2012
133. Crespin, S. R., Greenough, W. B. 3rd & Steinberg, D. Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. J. Clin. Invest. 52, 1979-1984 (1973
134. Stein, D. T., et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 97, 2728-2735 (1996
135. Briscoe, C. P., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278, 11303-11311 (2003
136. Itoh, Y., et al Free Fatty Acids Regulate Insulin Secretion from Pancreatic β Cells Through GPR40. Nature 422, 173-176 (2003
137. Latour, M. G., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56, 1087-1094 (2007
138. Stoddart, L. A., Brown, A. J., & Milligan, G. Uncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5? O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol. Pharmacol. 71, 994-1005 (2007
139. Poitout, V., & Robertson, R. P. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr. Rev. 29, 351-366 (2008
140. Yaney, G. C., & Corkey, B. E. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 46, 1297-1312 (2003
141. Alquier, T., et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58, 2607-2615 (2009
142. Kebede, M., et al. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57, 2432-2437 (2008
143. Lan, H., et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57, 2999-3006 (2008
144. Nagasumi, K., et al. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58, 1067-1076 (2009
145. Vettor, R., et al. Loss of function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J. Clin. Endocrinol. Metab. 93, 3541-3550 (2008
146. Doshi, L. S., et al. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Metabolism 58, 333-343 (2009
147. Luo, J., et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 7, e46300 (2012
148. Tan, C. P., et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57, 2211-2219 (2008
149. Tsujihata, Y., et al. TAK 875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 339, 228-237 (2011
150. Ferdaoussi, M., et al G protein-coupled receptor (GPR)40 dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55, 2682-2692 (2012
151. Fujiwara, K., Maekawa, F., & Yada, T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet β-cells: mediation by PLC and L type Ca2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 289, E670-E677 (2005
152. Shapiro, H., Shachar, S., Sekler, I., Hershfinkel, M., & Walker, M. D. Role of GPR40 in fatty acid action on the β cell line INS 1E. Biochem. Biophys. Res. Commun. 335, 97-104 (2005
153. Edfalk, S., Steneberg, P., & Edlund, H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57, 2280-2287 (2008
154. Flodgren, E., et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 354, 240-245 (2007
155. Wang, L., et al. Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet α-cells. J. Endocrinol. 210, 173-179 (2011
156. Burant, C. F., et al. TAK 875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379, 1403-1411 (2012
157. Yashiro, H., et al. The effects of TAK 875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 340, 483-489 (2012
158. Hirasawa, A., et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem. Biophys. Res. Commun. 365, 22-28 (2008
159. Ma, D., et al. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci. Res. 58, 394-401 (2007
160. Nakamoto, K., et al. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 1432, 74-83 (2012
161. Kebede, M., et al. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol 3 kinase-dependent O GlcNAcylation of pancreas-duodenum homeobox 1. Proc. Natl Acad. Sci. USA 109, 2376-2381 (2012
162. Mancini, A. D., & Poitout, V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?. Trends Endocrinol. Metab. 24, 398-407 (2013
163. Li, Y., et al β-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide 1. Diabetes 54, 482-491 (2005
164. Kalis, M., et al. Variants in the FFAR1 gene are associated with beta cell function. PLoS ONE 2, e1090 (2007
165. Dupuis, J., et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 42, 105-116 (2010
166. Wagner, R., et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 62, 2106-2111 (2013
167. Negoro, N., et al. Discovery of TAK 875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1, 290-294 (2010
168. Kaku, K., Araki, T., & Yoshinaka, R. Randomized, double-blind, dose-ranging study of TAK 875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36, 245-250 (2013
169. Defossa, E., & Wagner, M. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg. Med. Chem. Lett. 24, 2991-3000 (2014
170. Lin, D. C., et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol. Pharmacol. 82, 843-859 (2012
171. Xiong, Y., et al. Activation of FFA1 mediates GLP 1 secretion in mice. Evidence for allosterism at FFA1. Mol. Cell Endocrinol. 369, 119-129 (2013
172. Lin, D. C., et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 6, e27270 (2011
173. Chu, Z. L., et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide 1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149, 2038-2047 (2008
174. Chu, Z. L., et al. A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609 (2007
175. Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52, 289-298 (2009
176. Reimann, F., et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532-539 (2008
177. Hansen, K. B., et al. 2 oleoyl glycerol is a GPR119 agonist and signals GLP 1 release in humans. J. Clin. Endocrinol. Metab. 96, E1409-E1417 (2011
178. Overton, H. A., et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175 (2006
179. Soga, T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751 (2005
180. Hansen, H. S., Rosenkilde, M. M., Holst, J. J., & Schwartz, T. W. GPR119 as a fat sensor. Trends Pharmacol. Sci. 33, 374-381 (2012
181. Lauffer, L., Iakoubov, R., & Brubaker, P. L. GPR119: 'double-dipping' for better glycemic control. Endocrinology 149, 2035-2037 (2008
182. Lan, H., et al. GPR119 is required for physiological regulation of glucagon-like peptide 1 secretion but not for metabolic homeostasis. J. Endocrinol. 201, 219-230 (2009
183. Soga, T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 326, 744-751 (2005
184. Jones, R. M., Leonard, J. N., Buzard, D. J., & Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359 (2009
185. Shah, U., & Kowalski, T. J. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitam. Horm. 84, 415-448 (2010
186. Moran, B. M., Abdel-Wahab, Y. H., Flatt, P. R., & McKillop, A. M. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol. Chem. 395, 453-464 (2014
187. Lee, Y. S., et al. The fractalkine/CX3CR1 system regulates β cell function and insulin secretion. Cell 153, 413-425 (2013
188. Aoyama, T., Inokuchi, S., Brenner, D. A., & Seki, E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology 52, 1390-1400 (2010
189. Haskell, C. A., Cleary, M. D., & Charo, I. F. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1 expressing cells is independent of G protein activation. J. Biol. Chem. 274, 10053-10058 (1999
190. Lucas, A. D., et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am. J. Pathol. 158, 855-866 (2001
191. Combadiere, C., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107, 1009-1016 (2003
192. Imai, T., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521-530 (1997
193. Zernecke, A., Shagdarsuren, E., & Weber, C. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol. 28, 1897-1908 (2008
194. Cardona, A. E., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917-924 (2006
195. Tacke, F., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest. 117, 185-194 (2007
196. Inoue, A., et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 52, 1522-1533 (2005
197. Garton, K. J., et al. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276, 37993-38001 (2001
198. Hundhausen, C., et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1 mediated cell-cell adhesion. Blood 102, 1186-1195 (2003
199. Shah, R., et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60, 1512-1518 (2011
200. Sirois-Gagnon, D., et al. Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obes. (Silver Spring) 19, 222-227 (2011
201. Cnop, M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem. Soc. Trans. 36, 348-352 (2008
202. van Raalte, D. H., & Diamant, M. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?. Diabetes Res. Clin. Pract. 93, S37-S46 (2011
203. Donath, M. Y., Dalmas, E., Sauter, N. S., & Boni Schnetzler, M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17, 860-872 (2013
204. Eguchi, K., & Manabe, I. Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes. Metab. 15, 152-158 (2013
205. Ehses, J. A., Ellingsgaard, H., Boni-Schnetzler, M., & Donath, M. Y. Pancreatic islet inflammation in type 2 diabetes: from α and β cell compensation to dysfunction. Arch. Physiol. Biochem. 115, 240-247 (2009
206. Mancini, A. D., & Poitout, V. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes Obes. Metab. 17, 622-629 (2015